ORLANDO, Fla. — Of the 12 biologics in four drug classes approved for treating psoriasis in the United States, interleukin 23 (IL-23) inhibitors might be exceptional, particularly if used early ...

State Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, International ...

Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland ...

1. CAS Reg. No. 142797-34-0. 2. CAS Reg. No. 65666-07-1. 3. CAS Reg. No. 36804-18-9. BAY 2666605 1 is a phosphodiesterase 3 (PDE3) inhibitor that is being developed to combat melanoma. It is active ...

Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis.